Harbinger Times

The Tuberculosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Tuberculosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tuberculosis Market.

Some of the key takeaways from the Tuberculosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Tuberculosis treatment therapies with a considerable amount of success over the years. 
• Tuberculosis companies working in the treatment market are GlobeImmune, PDS Biotechnology, BioNTech, GlaxoSmithKline, Archivel Farma, GC Biopharma, Serum Institute of India Pvt. Ltd., Biofabri, S.L, Qurient Co, Shanghai Jiatan Pharmatech, Global Alliance for TB Drug Development, Theravectys, and others, are developing therapies for the Tuberculosis treatment 

• Emerging Tuberculosis therapies in the different phases of clinical trials are- GI-18000, PDS0201, BNT164, GSK2556286, GSK3036656, RUTI, GC3107A, VPM1002, MTBVAC, Telacebec, WX-081, TBAJ-876, Tuberculosis disease program, and others are expected to have a significant impact on the Tuberculosis market in the coming years.   
• In September 2022, Biofabri commenced a Phase III trial that is randomized, double-blind, and controlled. Its aim is to assess the effectiveness, safety, and immune response of MTBVAC in newborns who are both HIV unexposed and HIV exposed but uninfected, residing in Tuberculosis-Endemic areas within Sub-Saharan Africa.
• In March 2022, Bharat Biotech forged an alliance with Biofabri to collaboratively work on the development, production, and promotion of a novel Tuberculosis Vaccine. Bharat Biotech chose this vaccine candidate due to its progressed stage in clinical development and the encouraging outcomes observed in Phase I and Phase II clinical trials.
• In January 2022, The Phase II trial for pulmonary tuberculosis of GlaxoSmithKline’s GSK-3036656 led to a significant increase in its Phase Transition Success Rate (PTSR), rising by seven points to reach 55%.
• In March 2022, Bharat Biotech revealed a collaboration with Biofabri, a biopharmaceutical company from Spain, aimed at creating, producing, and introducing a new tuberculosis vaccine named ‘MTBVAC’. This partnership ensures the availability of TB vaccines across over 70 countries, with a particular focus on Southeast Asia and sub-Saharan Africa.
• In April 2022, Moderna and the non-profit scientific research group IAVI have joined forces in a fresh partnership to utilize mRNA technology. This collaboration aims to address various global health challenges, encompassing HIV/AIDS, tuberculosis (TB), antimicrobial-resistant enteric infections, and COVID-19.

Tuberculosis Overview

Lung disease is the most typical manifestation of tuberculosis (TB), an ancestor of human disease mostly caused by Mycobacterium tuberculosis. The respiratory system, gastrointestinal (GI) system, lymphoreticular system, skin, central nervous system, musculoskeletal system, reproductive system, and liver are the organ systems most frequently impacted.

Get a Free Sample PDF Report to know more about Tuberculosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/tuberculosis-pipeline-insight

Emerging Tuberculosis Drugs Under Different Phases of Clinical Development Include:

• GI-18000: GlobeImmune
• PDS0201: PDS Biotechnology
• BNT164: BioNTech
• GSK2556286: GlaxoSmithKline
• GSK3036656: GlaxoSmithKline
• RUTI: Archivel Farma
• GC3107A: GC Biopharma
• VPM1002: Serum Institute of India Pvt. Ltd.
• MTBVAC: Biofabri, S.L
• Telacebec: Qurient Co
• WX-081: Shanghai Jiatan Pharmatech
• TBAJ-876: Global Alliance for TB Drug Development
• Tuberculosis disease program: Theravectys

Tuberculosis Route of Administration

Tuberculosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Tuberculosis Molecule Type

Tuberculosis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Tuberculosis Pipeline Therapeutics Assessment

• Tuberculosis Assessment by Product Type
• Tuberculosis By Stage and Product Type
• Tuberculosis Assessment by Route of Administration
• Tuberculosis By Stage and Route of Administration
• Tuberculosis Assessment by Molecule Type
• Tuberculosis by Stage and Molecule Type

DelveInsight’s Tuberculosis Report covers around 35+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Tuberculosis product details are provided in the report. Download the Tuberculosis pipeline report to learn more about the emerging Tuberculosis therapies

Some of the key companies in the Tuberculosis Therapeutics Market include:

Key companies developing therapies for Tuberculosis are – GlaxoSmithKline, Archivel Farma S.L., LegoChem Biosciences, Quratis Inc, Qurient Co., Sequella, Inc., Vaxil Biotherapeutics, Tianjin CanSino Biotechnology, Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, Shanghai Jiatan Pharmatech, Global Alliance for TB Drug Development, BioNtech, TaBriX, Moderna, GC Biopharma, AJ Vaccines, Vaxxit Srl, Vaxil Bio Therapeutics, Vaxine Pty Ltd,  TVAX Biomedical, Theravectys SA, and others.

Tuberculosis Pipeline Analysis:

The Tuberculosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Tuberculosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tuberculosis Treatment.
• Tuberculosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Tuberculosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Tuberculosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Tuberculosis drugs and therapies

Tuberculosis Pipeline Market Drivers

• Increasing R&D Investments and new drug developments, rising incidence of Tuberculosis are some of the important factors that are fueling the Tuberculosis Market.

Tuberculosis Pipeline Market Barriers

• However, high pricing of drugs specially second line treatment, lack of TB diagnostics and other factors are creating obstacles in the Tuberculosis Market growth.

Scope of Tuberculosis Pipeline Drug Insight    

• Coverage: Global
• Key Tuberculosis Companies: GlobeImmune, PDS Biotechnology, BioNTech, GlaxoSmithKline, Archivel Farma, GC Biopharma, Serum Institute of India Pvt. Ltd., Biofabri, S.L, Qurient Co, Shanghai Jiatan Pharmatech, Global Alliance for TB Drug Development, Theravectys, and others
• Key Tuberculosis Therapies: GI-18000, PDS0201, BNT164, GSK2556286, GSK3036656, RUTI, GC3107A, VPM1002, MTBVAC, Telacebec, WX-081, TBAJ-876, Tuberculosis disease program, and others
• Tuberculosis Therapeutic Assessment: Tuberculosis current marketed and Tuberculosis emerging therapies
• Tuberculosis Market Dynamics: Tuberculosis market drivers and Tuberculosis market barriers 

Request for Sample PDF Report for Tuberculosis Pipeline Assessment and clinical trials

Table of Contents

1. Tuberculosis Report Introduction

2. Tuberculosis Executive Summary

3. Tuberculosis Overview

4. Tuberculosis- Analytical Perspective In-depth Commercial Assessment

5. Tuberculosis Pipeline Therapeutics

6. Tuberculosis Late Stage Products (Phase II/III)

7. Tuberculosis Mid Stage Products (Phase II)

8. Tuberculosis Early Stage Products (Phase I)

9. Tuberculosis Preclinical Stage Products

10. Tuberculosis Therapeutics Assessment

11. Tuberculosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Tuberculosis Key Companies

14. Tuberculosis Key Products

15. Tuberculosis Unmet Needs

16 . Tuberculosis Market Drivers and Barriers

17. Tuberculosis Future Perspectives and Conclusion

18. Tuberculosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/